NCT02257424已完成1 期
BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/II Open-Label Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- Phase 1: To determine the maximum tolerated dose
研究概览
简要总结
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be at least 18 years of age.
- •Patients must have histologically confirmed melanoma unresectable Stage III or Stage IV positive for BRAF V600E, V600K, V600R or V600D by a CLIA approved assay.
- •Patients must have an ECOG performance status of 0 or
- •Patients must have adequate baseline organ function as determined by table
- •Definitions for adequate baseline organ function
- •Laboratory Values
- •Hematologic:
- •ANC (absolute neutrophil count) ≥1.2 × 109/L
- •Hemoglobin ≥ 9 g/dL
- •Platelet count ≥100 x 109/L
- •PT/INR and PTT ≤ 1.3 x ULN (PT = prothrombin time; INR = international normalized ratio; PTT = partial thromboplastin time; ULN = upper limit of normal)
- •Total bilirubin ≤ 1.5 x ULN
- •AST (aspartate aminotransferase) and ALT (alanine transaminase) ≤ 2.5 x ULN
- •Renal -- Serum creatinine ≤ 1.5 mg/dL
- •- Left Ventricular Ejection fraction (LVEF) ≥ LLN (lower limit of normal) by ECHO
- •Subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization.
- •If serum creatinine is > 1.5 mg/dL, calculate creatinine clearance using standard Cockcroft-Gault formula. Creatinine clearance must be ≥ 50 mL/min to be eligible.
- •Except subjects with known Gilbert's syndrome. ECHO scans must be used throughout the study when indicated
- •Patients must be able to provide written informed consent.
- •Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year. Women must use an effective method of contraception from 14 days prior to randomization, throughout the treatment period, and for at least 6 months after the last dose of study treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, or intra-uterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.) Hormonal-based methods (e.g., oral contraceptives) are NOT permitted as contraception due to potential drug-drug interactions with dabrafenib.
- •Patients with brain metastases treated with whole brain radiation that have been stable for 2 months are eligible; patients with brain metastases treated with gamma knife or surgery are allowed to participate after 2 weeks have elapsed since their procedure. Subjects are excluded if they have leptomeningeal or metastases causing spinal cord compression that are symptomatic or untreated or not stable for ≥3 months (must be documented by imaging) or requiring corticosteroids. Subjects on a stable dose of corticosteroids >1 month or who have been off of corticosteroids for at least 1 week can be enrolled with approval of the medical monitor
- •Any number and type of prior anticancer therapies are allowed except BRAF or MEK inhibitors .
- •Patients must have discontinued active immunotherapy (IL-2, interferon, CTLA-4, etc.) or chemotherapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study. Patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry.
- •All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed in Eligibility Criteria #4) must be Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03, 2009) at the time of starting treatment. Patients that are asymptomatic on low dose maintenance hormone replacement delivered at a stable dose for prior toxicities are eligible.
- •Patient much have measurable disease as defined by RECIST 1.
- •Patients must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
排除标准
- •Patients with known serious concurrent infection or medical illness, including psychiatric disorders, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
- •Patients who are pregnant or breast-feeding.
- •Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).
- •Patients who are known to be experiencing an objective partial response to immunotherapy at the time of study enrollment
- •History of malignancy other than disease under study within 3 years of study enrollment with exceptions below:
- •Exception: Subjects with a history of completely resected non-melanoma skin cancer, or subjects with indolent second malignancies are eligible
- •History of malignancy with confirmed activating RAS mutation at any time. Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.
- •History of interstitial lung disease or chronic pneumonitis
- •Due to risk of disease exacerbation patients with porphyria or psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations.
- •Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).
- •Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatment
- •Current use of a prohibited medication as described in Section 6.3.8 of the protocol for Potential for Drug-Drug Interaction: apply moisturizing creams frequently, topical keratolytics (e.g. urea 20-40 % cream, salicylic acid 6%, tazarotene 0.1% cream, fluorouracil 5% cream), clobetasol propionate 0.05% ointment for erythematous areas, topical lidocaine 2%, and / or systemic pain medication such as nonsteroidal anti-inflammatory drugs, codeine, and pregabalin for pain.
- •Known Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and/or HCV will be permitted
- •Patients with a previously documented retinal vein occlusion.
- •History or evidence of increased cardiovascular risk including any of the following
- •Left ventricular ejection fraction (LVEF) < institutional lower limit of normal.
- •A QT interval corrected for heart rate using the Bazett's formula ≥ 480 msec;
- •Current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible.
- •History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
- •Current ≥ Class II congestive heart failure as defined by New York Heart Association
- •Patients with intra-cardiac defibrillators
- •Abnormal cardiac valve morphology (≥grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
研究组 & 干预措施
Phase 1/2
Other
干预措施: dabrafenib 150 mg orally twice a day (Drug)
Phase 1/2
Other
干预措施: Trametinib 2 mg daily (Drug)
Phase 1/2
Other
干预措施: hydroxychloroquine (HCQ) (Drug)
结局指标
主要结局
Phase 1: To determine the maximum tolerated dose
时间窗: 5 weeks
Phase 1: Maximum tolerated dose (MTD) = a) the dose producing Dose Limiting Toxicity (DLT) in 2/6 patients, or b) the dose level below the dose which produced DLT in ≥ 2/3 patients, or in ≥ 3/6 patients
Phase 2: To assess the clinical efficacy of HCQ+D+T by 1 year PFS rate.
时间窗: 1 year
Phase 2: Progression free survival (PFS) is defined as the duration of time from start of treatment to time of first progression, death due to any cause or last patient contact alive and progression-free
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
MCS110 With BRAF/MEK Inhibition in Patients With MelanomaMelanomaNCT03455764Dana-Farber Cancer Institute6
尚未招募
不适用
Therapeutic Drug Monitoring of BRAF- and MEK-inhibitors in a *Real Life* Cohort of Melanoma Patientsmalignancy10040900cancerNL-OMON38707Antoni van Leeuwenhoek Ziekenhuis120
已完成
不适用
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the USMelanomaNCT05260684Pfizer716
已完成
1 期
Systemic Therapy With Interferon, Interleukin-2 and BRAF InhibitorMelanomaNCT01603212M.D. Anderson Cancer Center6
进行中（未招募）
1 期
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEEUCTR2019-001399-13-FRHospices Civils de Lyon29